Deepshikha started her career in orthopedic device marketing in Japan. Thereafter she transitioned to marketing cardiovascular devices and subsequently moved to the US to lead regulatory teams in developing and implementing global regulatory strategies for cardiovascular/endovascular stents, Companion Diagnostic assays, Digital health solutions and NGS tests. At GRAIL her focus is on delivering on the mission – Finding Cancer Early, When it can Be Cured.
Alzheimer’s disease is one of our nation’s most significant threats, with devastating impacts on patients and their families. This session will explore a new approach called neurodiagnostic therapies, a methodology fundamentally enabled by ultrasensitive biomarker measurements that allow visibility to neurological disease in individuals before they are symptomatic. This allows treatment to be administered at a more optimal stage, to improve therapeutic effectiveness and by extension, patient outcomes.
During this presentation, attendees will learn how this new approach can provide early treatment to ultimately accelerate disease detection and improve outcomes, in addition to creating viable and credible evidence for the healthcare system to adopt it with coverage to facilitate frictionless access.